Providence TherapeuticsPresentation highlights data from PRO-CL-002 Phase 2 study of Providence’s mRNA COVID-19 vaccine candidate, PTX-COVID19-BPTX-COVID19-B was well tolerated with no safety signals; non-inferior to comparator vaccine, Comirnaty® with respect to neutralizing antibody titersCALGARY, Alberta, Nov. 28, 2022 (GLOBE NEWSWIRE) — Providence Therapeutics Holdings Inc. (“Providence”) today announced that Aleksandra Pastrak, M.D., Ph.D., chief medical officer of Providence Therapeutics, will deliver a presentation highlighting Phase 2 data on PTX-COVID19-B, the company’s mRNA COVID-19 vaccine candidate, at the World Vaccine & Immunotherapy Congress taking place in San Diego, California on November 28 – December 1, 2022. The presentation will take place November 29, 2022, at 2:20pm PST.“With COVID-19 now endemic, it’s important to be sure we have a variety of safe and effective vaccine options available to distribute around the globe for further protection from the virus,” said Dr. Pastrak. “Phase 2 data have shown that PTX-COVID19-B is comparable to Pfizer and BioNTech’s widely used COVID-19 mRNA vaccine with respect to neutralizing antibody concentration at two weeks following the second of two doses. This data is a strong scientific and developmental validation of the work that has been accomplished at Providence. We look forward to initiating a Phase 3 trial in a booster setting following these encouraging safety and immunogenicity results.”The presentation highlights positive top-line data from the PRO-CL-002 Phase 2 study evaluating the safety, tolerability and immunogenicity of Providence’s mRNA COVID-19 vaccine candidate, PT …
